- Home
- CURR vs EDIT Comparison
CURR vs EDIT Comparison
Compare CURR & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- EDIT
- Stock Information
- Founded
- CURR 2013
- EDIT 2013
- Country
- CURR Singapore
- EDIT United States
- Employees
- CURR N/A
- EDIT N/A
- Industry
- CURR Business Services
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CURR Consumer Discretionary
- EDIT Health Care
- Exchange
- CURR Nasdaq
- EDIT Nasdaq
- Market Cap
- CURR 133.1M
- EDIT 108.1M
- IPO Year
- CURR N/A
- EDIT 2016
- Fundamental
- Price
- CURR $1.83
- EDIT $1.92
- Analyst Decision
- CURR
- EDIT Buy
- Analyst Count
- CURR 0
- EDIT 14
- Target Price
- CURR N/A
- EDIT $8.08
- AVG Volume (30 Days)
- CURR 569.7K
- EDIT 5.8M
- Earning Date
- CURR 03-04-2025
- EDIT 03-03-2025
- Dividend Yield
- CURR N/A
- EDIT N/A
- EPS Growth
- CURR N/A
- EDIT N/A
- EPS
- CURR N/A
- EDIT N/A
- Revenue
- CURR $48,723,898.00
- EDIT $61,759,000.00
- Revenue This Year
- CURR N/A
- EDIT N/A
- Revenue Next Year
- CURR N/A
- EDIT N/A
- P/E Ratio
- CURR N/A
- EDIT N/A
- Revenue Growth
- CURR N/A
- EDIT 150.95
- 52 Week Low
- CURR $1.19
- EDIT $1.12
- 52 Week High
- CURR $7.08
- EDIT $11.58
- Technical
- Relative Strength Index (RSI)
- CURR N/A
- EDIT 55.72
- Support Level
- CURR N/A
- EDIT $1.12
- Resistance Level
- CURR N/A
- EDIT $3.30
- Average True Range (ATR)
- CURR 0.00
- EDIT 0.30
- MACD
- CURR 0.00
- EDIT 0.12
- Stochastic Oscillator
- CURR 0.00
- EDIT 36.70
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.